Unexpected bonus: blocking STAT3 could help cancer patients in two ways

The STAT transcription factors are involved in the development of many forms of cancer. STAT3 is frequently activated in tumor cells, so drugs targeting STAT3 could be used in cancer therapy. However, STAT3 is also important in the development of the immune system. Researchers now show that blocking STAT3 in cells of the immune system actually leads to increased anti-tumor immunity. Anti-STAT3 therapy may thus be highly promising.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Publication date: Available online 23 May 2019Source: Biochimica et Biophysica Acta (BBA) - BiomembranesAuthor(s): Andrei Sakai, Ana Paula de Sousa Mesquista, Erica Valadares de Castro Levatti, Anita Hilda Straus, Helena B. Nader, Carla Cristina Lopes, Luciano CaseliAbstractTrastuzumab (Tmab) is a monoclonal antibody administered as targeted therapy for HER2-positive breast cancer whose molecular interactions at the HER2 receptor microenvironment are not completely clarified yet. This paper describes the influence of Tmab in the molecular organization of films of biological-relevant molecules at the air water interface. Fo...
Source: Biochimica et Biophysica Acta (BBA) Biomembranes - Category: Biochemistry Source Type: research
Authors: Espelt MV, Bacigalupo ML, Carabias P, Troncoso MF Abstract Hepatocellular carcinoma (HCC) has an elevated mortality rate, largely because of high recurrence and metastasis. Additionally, the main obstacle during treatment of HCC is that patients usually develop resistance to chemotherapy. Cancer drug resistance involves many different mechanisms, including alterations in drug metabolism and processing, impairment of the apoptotic machine, activation of cell survival signaling, decreased drug sensitivity and autophagy, among others. Nowadays, miRNAs are emerging as master regulators of normal physiology- an...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Publication date: August 2019Source: European Polymer Journal, Volume 117Author(s): Xi Pan, Jingru Chen, Mengdan Yang, Jie Wu, Guanghua He, Yihua Yin, Meng He, Wenjin Xu, Peihu Xu, Weiquan Cai, Fanglin ZhangAbstractFor enhanced stability and anticancer efficacy, the 10-Hydroxycamptothecin (10-HCPT) structure based pH/enzyme responsive polymeric prodrug nanoparticles were constructed by conjugating 10-HCPT to carboxymethylchitosan (CMCS) via pH/enzyme sensitive succinyl linkage followed by ultrasonic dispersion. At pH 7.4 the nanoparticles exhibited a core–shell structure and good in vitro stability with very little d...
Source: European Polymer Journal - Category: Chemistry Source Type: research
Sun Hongbing Qin Increased glycolysis in tumor cells is associated with increased risk of tumor progression and mortality. Therefore, disruption of glycolysis, one of the main sources of cellular energy supply, can serve as a target for suppressing tumor growth and progression. Of note, hexokinase-2 (HK2) plays vital roles in glucose metabolism. Moreover, the expression of HK2 alters the metabolic phenotype and supports the continuous growth of tumor cells, making it an attractive target for cancer therapy. Quercetin (QUE), a bioactive flavonoid, has a profound anti-tumor effect on hepatocellular carcinoma (HCC), bu...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Introduction: The polymorphic enzyme cytochrome P450 2D6 (CYP2D6) catalyzes a major step in the bioactivation of tamoxifen. Genotyping of clinically relevant CYP2D6 alleles and subsequent dose adjustment is a promising approach to individualize breast cancer therapy. The aim of this study was to investigate the relationship between the plasma levels of tamoxifen and its metabolites and different CYP2D6 genotypes under standard (20 mg/d) and dose-adjusted therapy (Registration ID in Iranian Registry of Clinical Trials: IRCT2015082323734N1). Material and methods: Using TaqMan® assays common alleles of CYP2D6 (*1, *2, *4...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
In this study, we disclosed our finding that SBP could enhance the effective treatment performance of gemcitabine (GEM) while minimizing the toxic side effects caused by GEM. Mechanistically, SBP increased tumor angiogenesis, blood perfusion, vascular permeability and vessel dilation, which subsequently favored the delivery of GEM to the tumor lesion. Moreover, combined treatment with SBP and GEM could modify tumor microenvironment and consequently overcome multidrug resistance, and this combination therapy is also suitable for combination of SBP with some other chemotherapeutic drugs as well. These results suggest that co...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Emily Roarty Jing Wang Fei Yang Michelle Barton Jeffrey Rosen Sendurai Mani Over the last decade, both early diagnosis and targeted therapy have improved the survival rates of many cancer patients. Most recently, immunotherapy has revolutionized the treatment options for cancers such as melanoma. Unfortunately, a significant portion of cancers (including lung and breast cancers) do not respond to immunotherapy, and many of them develop resistance to chemotherapy. Molecular characterization of non-responsive cancers suggest that an embryonic program known as epithelial-mesenchymal transition (EMT), which is ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 23 May 2019Source: Pharmacology &TherapeuticsAuthor(s): Junko Murai, Anish Thomas, Markku Miettinen, Yuves PommierAbstractSchlafen 11 (SLFN11) sensitizes cells to a broad range of anti-cancer drugs including platinum derivatives (cisplatin and carboplatin), inhibitors of topoisomerases (irinotecan, topotecan, doxorubicin, daunorubicin, mitoxantrone and etoposide), DNA synthesis inhibitors (gemcitabine, cytarabine, hydroxyurea and nucleoside analogues), and poly(ADPribose) polymerase (PARP) inhibitors (olaparib, rucaparib, niraparib and talazoparib). In spite of their different primary...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 22 May 2019Source: International Journal of PharmaceuticsAuthor(s): Patrícia Cerqueira, Jennifer Noro, Sofia Moura, Diana Guimarães, Carla Silva, Artur Cavaco-Paulo, Ana LoureiroAbstractPolyoxyethanyl-α-tocopheryl sebacate (PTS) is an amphiphilic compound with self-emulsifying properties known to form micelles. In this work, we report the production of PTS micelles for the encapsulation and delivery of a hydrophobic derivative of methotrexate, MTX di-ethylated (MTX-OEt). We optimized the micelles production by testing two different techniques: auxiliary solvent and son...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
In this study, the elucidation of mechanisms underlying the anticancer effects of the apigenin, luteolin and myricetin will be new knowledge about preventive strategies against epithelial ovarian cancer in which the effect of flavonoids is still unclear. The cytotoxic effect of flavonoids was assessed by MTT analysis of the ovarian cancer cells (A2780, OVCAR-3 and SKOV-3) in comparison to the ovarian epithelial cells (OSE). The intracellular reactive oxygen species (ROS) generation, malondialdehyde (MDA) and protein carbonyl levels, caspase-3 and -9 activities were evaluated using fluorescence spectrometry. Apoptosis and c...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Science